Edwards Lifesciences (EW) Operating Expenses (2009 - 2026)

Edwards Lifesciences has reported Operating Expenses for 18 years, with the latest figure at $822.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 13.54% year-over-year to $822.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 billion (up 9.22% YoY), and the FY2025 full-year result was $3.2 billion, up 10.23% from the prior year.
• Operating Expenses for Q1 2026 stood at $822.6 million, up from $766.9 million in the prior quarter.
• The five-year high for Operating Expenses was $822.6 million in Q1 2026, with the low at $381.5 million in Q4 2022.
• Average Operating Expenses over 5 years is $696.8 million, with a median of $719.3 million recorded in 2024.
• Year-over-year, Operating Expenses tumbled 42.54% in 2022 and soared 75.26% in 2023.
• Tracing EW's Operating Expenses over 5 years: stood at $381.5 million in 2022, then soared by 75.26% to $668.6 million in 2023, then advanced by 15.24% to $770.5 million in 2024, then dropped by 0.47% to $766.9 million in 2025, then grew by 7.26% to $822.6 million in 2026.
• The last three Operating Expenses figures came in at $822.6 million (Q1 2026), $766.9 million (Q4 2025), and $795.4 million (Q3 2025), per Business Quant data.

Peer Comparison